Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: A multiple criteria decision analysis

J. C. Hsu, D. H. Tang, C. Y. Lu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background Erectile dysfunction (ED) is a common male sexual disorder worldwide. Three oral phosphodiesterase type 5 inhibitors (PDE5Is)-sildenafil, tadalafil and vardenafil-are available for treatment of ED. This study quantitatively evaluated the therapeutic efficacy and safety of these medications to assist treatment decision making. Methods We used multiple criteria decision analysis (MCDA) to assess the totality of risk-benefit of PDE5Is. We created two models: (i) the overall model included 'overall improvement in erections' and 'any adverse events' and (ii) the detailed model included 'erectile function domain', 'ability for sexual intercourse', 'duration of erection last', 'serious adverse events', 'headache', 'flushing' and 'dyspepsia'. We calculated a synthetic utility for each drug accounting for all of its benefits and risks. Results Considering the overall risk-benefit, vardenafil had the highest synthetic utility among three medications; in the order of synthetic utilities: vardenafil (0.568), tadalafil (0.478) and sildenafil (0.437). However, when specific risk and benefit criteria were assessed, tadalafil had the highest synthetic utility (0.602) according to the conjoint evaluation (synthetic utility for vardenafil is 0.491 and sildenafil is 0.442, respectively). The sensitivity analysis based on the uncertainties of weight on risks of any adverse events (including serious adverse events and headache) suggested our results were robust. Conclusions This study provides a useful approach that comprehensively and systematically assesses and compares the risk-benefit of several treatment alternatives. Our study not only rank treatment alternatives by synthetic utilities based on the risk-benefit balance but also compare specific risk and benefit criteria between these medicines. Our results provide valuable evidence that can guide clinicians and patients in making treatment decisions.

Original languageEnglish
Pages (from-to)436-443
Number of pages8
JournalInternational Journal of Clinical Practice
Volume69
Issue number4
DOIs
Publication statusPublished - Apr 1 2015
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: A multiple criteria decision analysis'. Together they form a unique fingerprint.

  • Cite this